From Trace Alkaloid to Schedule I: The Kratom and 7-OH Story

How a molecule barely present in the kratom leaf was concentrated far beyond natural levels, sold in everyday consumer products, and is now the subject of a federal notice of intent to place it in Schedule I, the same controlled-substance category as heroin.

A compound can exist quietly in a plant for centuries and attract little attention. Then someone concentrates it.

That, in essence, is the story of 7-hydroxymitragynine, better known as 7-OH.

Consider the scale. In natural kratom leaf, 7-OH is a minor alkaloid: a gram of dried leaf carries only about 0.1 to 0.4 milligrams of it.¹ A single concentrated gas-station tablet, by contrast, can contain as much as 700 milligrams in one serving.² Manufacturers have learned to isolate, enrich, and formulate 7-OH far beyond what occurs naturally, concentrating it into tablets, liquid shots, gummies, and vapes sold online and through gas stations and smoke shops, sometimes under wellness or energy branding. These products have been dubbed "gas-station opioids."²

The critical question is not simply, "Does this compound come from a plant?" The better question is, "Does the finished product still resemble the exposure a person would receive from that plant?" In the case of concentrated 7-OH, that distinction may determine whether a product is viewed as a botanical preparation or as a potent opioid that belongs under federal controlled-substance law.

For anyone in supplements, functional foods, ingredient supply, investment, or product-liability law, this is more than a kratom story. It is a case study in what happens when product innovation outruns toxicology, quality systems, and regulatory strategy.

---

First, what is kratom?

Kratom (Mitragyna speciosa) is a tropical evergreen tree in the coffee family, native to Southeast Asia. For generations, people across Thailand, Malaysia, and Indonesia have chewed the fresh leaves or brewed them as tea to fight fatigue, manage pain, and ease opioid withdrawal. The leaf contains more than 40 alkaloids, naturally occurring compounds that produce biological effects, and the most abundant is mitragynine.

Kratom is unusual because its reported effects can change with dose. At lower doses, users often describe increased energy, alertness, and focus. At higher doses, the effects become more sedating and pain-relieving, with clear opioid-like characteristics. That happens because kratom is not pharmacologically simple: its major alkaloids interact with several signaling systems in the brain. Most importantly, mitragynine and related compounds act on mu-opioid receptors, part of the same receptor system targeted by morphine and other opioids, although mitragynine itself is a relatively weak and atypical opioid compared with conventional opioids.³

And this is where 7-OH changes the story.

The tiny alkaloid with outsized importance

7-OH is also in kratom, but only in tiny amounts. In natural leaf, it usually sits well below 0.1% of the plant material. On paper, that makes it sound like a minor footnote. It is not.

7-OH matters for two reasons. First, it is far stronger at the brain's opioid receptors than mitragynine. Second, the body makes its own: after you take kratom, the liver turns some mitragynine into 7-OH, and that step appears to do much of the work behind kratom's pain relief.³

So a person can end up exposed to 7-OH in two very different ways. One starts with the leaf: you take in mostly mitragynine, and your body makes a little 7-OH from it. The other route begins with a manufactured product. The 7-OH has already been isolated, enriched, chemically produced, or deliberately concentrated before the consumer takes it. Those two are not the same, and that gap is what the whole fight is about.

Why concentration changes everything

Picture a compound present at a fraction of a percent in a leaf. Now picture a manufacturer deliberately raising it far above that level and pressing it into a tablet, gummy, or shot. The source may still trace back to a plant, but the exposure is no longer meaningfully botanical.

The evidence explains why regulators treat that shift so seriously. The FDA's assessment reports that 7-OH binds strongly to mu-opioid receptors and shows potency exceeding morphine in several preclinical models.¹ In a rat self-administration study, the standard laboratory test for abuse potential, 7-OH substituted for morphine and was readily self-administered, while mitragynine did not; in fact, prior exposure to mitragynine reduced later morphine intake.⁴ A separate study found that human plasma metabolism does not simply deactivate 7-OH but can increase its opioid potency.⁵

Treating "kratom" and "concentrated 7-OH" as the same thing hides that distinction. They are related. They are not the same product.

How kratom acts on the brain

To see why concentration matters so much, it helps to know what these compounds do in the brain.

Kratom is a neuroactive plant, which simply means its active compounds work directly on the brain and nervous system. The main target is the mu-opioid receptor, the switch that controls pain relief, reward, drowsiness, dependence, and breathing, and 7-OH flips that switch much harder than mitragynine does. But mitragynine does more than opioids. Lab studies show it also acts on the brain's adrenergic system, which drives alertness,⁶ and its serotonin system, which helps set mood.⁷

That mix explains something that confuses a lot of people: how can one leaf feel like a stimulant at a low dose and a sedative at a higher one? Different compounds and receptors take over at different doses. But when a maker sharply concentrates 7-OH, that balance breaks. The product stops acting like a leaf and starts acting like a strong opioid, because it now carries a heavy dose of the plant's most opioid-like compound. That is the turning point in the whole story.

Why people use kratom and 7-OH products

People use these products for real reasons: pain, energy and focus, mood and anxiety, and very often to handle opioid cravings or withdrawal. Some see kratom as a legal, easy-to-get stand-in for prescription opioids.

None of these are uses the FDA has approved. Kratom is not approved as a drug, it is not legal to sell as a dietary supplement, and it cannot legally be added to food, and most of the support for these uses comes from personal reports rather than controlled studies.⁸ That is the hard part: a product can genuinely help the people who use it and still lack the testing, steady dosing, and safety checks we expect from a medicine.

Where concentrated 7-OH products show up

This is not a hypothetical concern about what manufacturers might one day do. Concentrated 7-OH is already an active ingredient in products on shelves. The DEA's July 2026 Federal Register notice describes 7-OH sold through smoke shops, gas stations, and online vendors as tablets, liquid shots, capsules, powders, syrups, vapes, sublingual pouches and strips, nasal sprays, chewables, and extracts.²

One investigation cited in that notice identified 250 products sold between September 2024 and February 2025, most often as chewable or sublingual tablets marketed for general wellbeing and focus. The 7-OH content ranged from 1 mg to 700 mg in a single serving.² That roughly 700-fold spread, sold beside snacks and phone chargers, is the heart of the concern: potent opioid-active products are reaching consumers without the dosing controls, pharmacy oversight, and risk management that accompany approved opioid medicines.

The benefits people report, and the risks that cannot be ignored

An honest account has to hold both sides. People report real benefits: pain relief, a lift in energy at low doses, better daily function, and help easing off stronger opioids. Some researchers have even looked at mitragynine's unusual opioid profile as a possible starting point for safer painkillers.³

The risks are just as real. Because these compounds act on opioid receptors, regular use can lead to tolerance, dependence, and an opioid-style withdrawal of restlessness, aches, sweating, and poor sleep. Concentrated 7-OH raises the stakes. The FDA calls it a potent opioid and points to clear warning signs: animals will dose themselves with it, it causes physical dependence and withdrawal, and it can slow breathing.¹ On top of that, products vary wildly, so two that look alike can deliver very different doses, they can be contaminated, and their alkaloids can interfere with the liver enzymes that process other medicines. It all comes down to one line: manufacturing can expose people to a strong opioid at levels the plant itself never makes.

What the newer science is showing

The big change in recent kratom research is a clear split between mitragynine and 7-OH. The two do not carry equal risk. In lab studies, mitragynine shows a low risk of addiction, what scientists call low abuse liability, while 7-OH behaves much more like morphine. In a self-administration study, the standard test for addiction risk, lab animals kept dosing themselves with 7-OH but not with mitragynine, and the researchers named 7-OH as the one to worry about.⁴ Regulators routinely use controlled animal studies like this to judge how addictive a drug is, especially when testing it on people would be unsafe or unethical.

There is human evidence too, and it is more real-world than clinical. It comes from user surveys, doctors' case reports, and poison-control data rather than large trials. The signals are hard to dismiss: between January and July 2025, U.S. poison centers logged 165 exposure cases involving 7-OH, and among people who took 7-OH alone, about a third had serious health effects.² That real-world picture matches the lab findings, with tolerance, dependence, opioid-like withdrawal, and the worst outcomes concentrated in the strongest products. The FDA's 2025 assessment drew on both the animal and the human evidence.¹

The market keeps changing too. Newer lab-made relatives of 7-OH have appeared, including mitragynine pseudoindoxyl, MGM-15, and MGM-16. HHS and FDA say these do not occur naturally in the plant,¹¹ and the United Nations Office on Drugs and Crime issued an alert about them in 2025.¹² This is no longer only a question about a traditional botanical. It is a question about what modern chemistry can build from it.

The regulatory shift: what Schedule I actually means

On July 29, 2025, the FDA formally recommended that concentrated 7-OH be placed in Schedule I of the Controlled Substances Act.⁹ For readers outside regulatory law, that phrase deserves a plain definition.

Schedule I is the most restrictive tier of federal drug law, reserved for substances judged to have high abuse potential, no currently accepted medical use, and no accepted safety even under medical supervision. Heroin and LSD sit here. It is deliberately different from Schedule II, where morphine and oxycodone reside: those carry serious risks but have accepted medical uses and can be prescribed under strict controls. Moving concentrated 7-OH toward Schedule I is therefore not a labeling tweak. It would fundamentally change how the federal government treats the substance.

The timeline matters because the action is active but not final. The DEA filed its notices of intent on July 1, 2026,^10,2 after HHS concluded that the substances meet the criteria of high abuse potential and no accepted medical use.¹¹ The essential point bears repeating: as of July 2026 this is a notice of intent, not an effective order. The notice states the temporary scheduling order will not publish before August 5, 2026, and once issued it can run for two years, extendable by one more while permanent scheduling is pursued.² Saying 7-OH "is already Schedule I" would misstate the law. The accurate statement is that qualifying concentrated 7-OH is the target of an active and imminent federal Schedule I action.

The threshold that matters: 0.050%

The action does not target "all kratom." It draws the line by concentration. It covers botanical kratom with more than 0.050% 7-OH by dry weight, and synthetic or processed material with more than 0.050% 7-OH by weight or volume, or more than 1.00 milligram of 7-OH per product.²

That turns one small number, 0.050%, into a big deal. For a company, it is not a science footnote. It is a formulation question, a supplier question, a certificate-of-analysis question, a testing question, a batch-release question, and, if the number is wrong, a controlled-substance question.

Kratom leaf below the line is not pulled into this Schedule I action. HHS and FDA have said the action is not meant to cover natural leaf without added 7-OH.¹¹ But not scheduled does not mean approved. The FDA still says kratom cannot legally be sold as a supplement or added to food, and Import Alert 54-15 is still in force.¹³ That is legal limbo, not a green light. A product can stay off the controlled-substance list and still face trouble over adulteration, unproven claims, import holds, labeling, state law, and lawsuits. Treating "not banned" as "cleared" is a common and expensive mistake.

The debate is more complicated than "safe" versus "dangerous"

There is a real policy tension here, and it deserves a fair hearing. Supporters argue the natural leaf can help some people manage pain or come off opioids, and they warn that a heavy-handed ban could push users toward more dangerous street drugs. That worry is legitimate. Regulators have the opposite worry: concentrated and synthetic 7-OH can act like a strong opioid while being sold with none of the safeguards that apply to opioid medicines, no prescription, no set dose, no approved use, no oversight.

The approach taking shape tries to separate these issues instead of lumping every kratom product together. Natural, low-level leaf is one question. Heavily enriched 7-OH is another. The 0.050% line is where regulators are splitting the two. People will keep debating whether that line sits in the right place, but the logic of separating a plant from a concentrated opioid is easy to follow.

The bigger lesson is not really about kratom

Step back, and the 7-OH story is not really about one plant.

A company starts with a botanical. Scientists find dozens of compounds in it. One stands out as especially active. Someone isolates it, then enriches it, then pushes the dose higher, then packages it in new formats with bigger claims. Reports of harm and dependence pile up. Then regulators step in. By the time the legal team asks whether the product crossed a line, the question that mattered was never asked earlier: does the final product still look anything like the plant it came from?

"Naturally occurring" only tells you where a molecule is found. It does not prove that every dose, concentration, or delivery method is natural, safe, legal, or defensible. A trace compound can turn into a completely different legal problem once someone concentrates it.

If your business builds, makes, sells, funds, or advises on botanical products, the 7-OH case is worth turning into a checklist, one to run at the start of development, not after a warning letter:

• Are you looking at the whole ingredient, or just the plant's name?
• Do you know which minor compounds matter once they are concentrated?
• Are your supplier limits based on real safety thresholds?
• Can your lab actually measure the compounds regulators care about?
• Does your certificate of analysis test for the right things?
• Has processing changed the plant's natural chemistry?
• Could the body turn it into something stronger after it is taken?
• Are your marketing claims nudging people to use it like a drug?
• Is your regulatory plan keeping up with formula changes?

Conclusion: a trace compound can become an existential risk

The 7-OH story started with a compound barely present in a leaf. It did not stay there. Extraction, enrichment, formulation, and marketing changed the exposure, the science raised real opioid and addiction concerns, and now a cutoff as small as 0.050% may decide whether a product stays outside federal control or lands in Schedule I.

For anyone working with botanicals, supplements, and functional foods, the lesson is bigger than kratom. What a product is, in the eyes of the law, depends not only on where the ingredient comes from, but on what processing does to it, how much is in it, how the body handles it, and how it is sold. That is why the science and the regulatory strategy cannot be handled separately. A product can start with a plant. One decision about concentration can change everything.